By Dr. Benjamin Caplan, MD | Board-Certified Family Physician, CMO at CED Clinic | Evidence Watch
A controlled crossover trial in 35 infrequent cannabis users found that inhaling CBD alongside THC significantly increased THC blood levels compared to THC alone, contradicting the common assumption that CBD blunts THC exposure. The finding has direct implications for cannabis product labeling, harm-reduction messaging, and clinical dosing strategies, though the small sample and sparse blood sampling warrant cautious interpretation.
CBD in Vaporised Cannabis Raises THC Blood Levels, Study Finds
A randomised, double-blind, placebo-controlled crossover trial demonstrates that co-inhaled CBD at a 3:1 ratio with THC significantly elevated circulating THC and its metabolites in infrequent cannabis users, with no clear pharmacokinetic differences detected between adolescents and adults, though the study’s small analysed sample and unregistered analysis plan call for cautious interpretation.
#78
Strong Clinical Relevance
One of very few controlled human studies examining inhaled CBD-THC pharmacokinetic interactions, with direct implications for dosing guidance and harm reduction in clinical cannabis practice.
Pharmacokinetics
Vaporised Cannabis
Adolescent Safety
Harm Reduction
A widely held belief among consumers and some clinicians is that CBD in cannabis products “balances” or mitigates THC’s intoxicating effects. If CBD actually increases THC blood levels when both compounds are inhaled together, this fundamentally changes how we should counsel patients about product selection and dosing. With high-CBD cannabis strains and vaporizer cartridges marketed as gentler alternatives, the clinical stakes of getting this pharmacokinetic question right are substantial. Adolescents, who represent a particularly vulnerable population for cannabis-related harm, were included in this study for the first time in controlled pharmacokinetic research.
The interaction between CBD and THC when co-administered has been debated for decades, with oral studies generally suggesting CBD inhibits the hepatic CYP enzymes responsible for THC metabolism, thereby raising THC concentrations. Whether this interaction also occurs through the inhaled route has been less clear, as several prior inhalation studies found no such effect. The CannTeen Acute study was originally designed to compare behavioral and cognitive responses to cannabis between adolescents and adults. This secondary pharmacokinetic analysis used pharmaceutical-grade vaporised cannabis (Bedrocan products) at weight-adjusted doses of 8 mg THC per 75 kg alone, or combined with 24 mg CBD per 75 kg, in a three-arm crossover design that also included placebo.
Among the 35 participants with complete blood data, the THC-plus-CBD condition produced significantly higher plasma THC area-under-the-curve and peak concentrations compared to THC alone. Both the active metabolite 11-OH-THC and the inactive metabolite THC-COOH were also elevated under the combined condition, with the exception of OH-THC peak concentration, which did not reach statistical significance. No robust pharmacokinetic differences between adolescents (ages 16 to 17) and adults (ages 26 to 29) were detected, though the study was explicitly underpowered for this comparison. The authors acknowledge that only four blood draws across 160 minutes yield imprecise AUC estimates, and that the pharmacokinetic analysis was not pre-registered. They call for replication with denser sampling, multiple dose ratios, and larger samples before these findings should influence clinical guidance.
This study challenges a narrative I hear constantly: that adding CBD to a cannabis product makes it “safer” or “less intense.” What the data actually show is that at a 3:1 CBD:THC ratio delivered by vaporizer, the CBD appears to increase how much THC enters the bloodstream. That is an important signal. But I want to be careful not to overstate what 35 participants, four blood draws, and a single dose ratio can tell us. The pharmacokinetic picture here is necessarily coarse. We do not yet know whether this interaction is linear across doses, whether it persists with regular use, or how it maps onto subjective experience and impairment.
In my practice, I already counsel patients that CBD is not a guaranteed antidote to THC’s effects, and this study reinforces that message. When patients are selecting vaporized products, I encourage starting with the lowest effective THC dose rather than relying on CBD content as a safety buffer. For adolescent patients and their families, these findings underscore why the “it’s mostly CBD” framing of certain products can be misleading. I will continue to monitor the replication literature closely before making stronger claims in either direction.
This study sits at an early but important point in the research arc for inhaled cannabinoid pharmacokinetics. Most prior controlled inhalation studies (Arkell et al., 2019; Nadulski et al., 2005) did not find a significant CBD effect on THC blood levels, making this result noteworthy as a possible exception or as evidence that the interaction may depend on dose ratio, delivery method, or user tolerance. The inclusion of adolescents is novel and addresses a genuine gap in the literature, though the null age finding should be interpreted as inconclusive rather than definitive. As a secondary, unregistered analysis from a parent trial designed for behavioral outcomes, the pharmacokinetic findings carry somewhat less evidentiary weight than a purpose-built pharmacokinetic study would.
From a pharmacological standpoint, the proposed mechanism involves CBD inhibition of CYP2C9 and CYP3A4, the principal enzymes responsible for THC hydroxylation and oxidation. If confirmed, this interaction would be relevant not only for recreational cannabis products but also for patients using medical cannabis alongside other medications metabolized by the same enzyme pathways, including warfarin, certain statins,
Have thoughts on this? Share it:
